Cholinergic Pharmacology

The most clinically useful distinction within this class is the physical chemistry of the drug molecule. Quaternary ammonium compounds carry a permanent positive charge and cannot cross lipid membranes, including the blood-brain barrier. They produce no central nervous system effects at therapeutic doses. Tertiary amines are uncharged at physiologic pH, cross membranes readily, and have the potential for central nervous system activity. This single structural difference determines the adverse effect profile of every drug in this class.

Bethanechol is a quaternary compound with selective muscarinic activity and no meaningful nicotinic effects. It does not cross the blood-brain barrier. Its primary indication is non-obstructive urinary retention, including postoperative and postpartum retention and neurogenic bladder with reduced detrusor contractility. It is given orally or by subcutaneous injection; intravenous use is avoided because it can provoke severe bradycardia and bronchospasm.

Bethanechol is contraindicated in mechanical urinary or bowel obstruction (muscarinic stimulation worsens the obstruction), peptic ulcer disease (increased gastric acid secretion), and asthma or chronic obstructive pulmonary disease (bronchoconstriction through muscarinic subtype 3 receptors in airway smooth muscle).

Pilocarpine is a tertiary amine and the only direct muscarinic agonist in clinical use with meaningful central nervous system penetration. Its actions are mediated primarily through muscarinic subtype 3 receptors: miosis (contraction of the sphincter pupillae), ciliary muscle contraction (shifting the eye toward near-vision accommodation), and stimulation of exocrine gland secretion.

Pilocarpine has three established clinical uses. As topical eye drops, it lowers intraocular pressure in open-angle glaucoma by improving drainage through trabecular meshwork outflow. In acute angle-closure glaucoma, it produces rapid miosis to relieve the pupillary block causing the pressure crisis. Given orally, it treats xerostomia (dry mouth) caused by Sjogren syndrome or radiation therapy to the head and neck, stimulating residual salivary gland secretion. The most common adverse effect is diaphoresis (excessive sweating) from eccrine sweat gland stimulation.

Carbachol is a quaternary compound that activates both muscarinic and nicotinic receptors, distinguishing it from the more selective bethanechol. Its combined receptor activity limits systemic use but makes it useful for intraocular applications. It is instilled directly into the anterior chamber during cataract surgery to produce miosis at the time of lens implantation, and it is used as a second-line topical agent for open-angle glaucoma when pilocarpine is inadequate or not tolerated.

Methacholine is a selective muscarinic agonist with no established therapeutic use. Its only clinical role is as a diagnostic tool: the methacholine bronchoprovocation test. When inhaled in incremental concentrations, methacholine stimulates muscarinic subtype 3 receptors in airway smooth muscle and produces bronchoconstriction in proportion to baseline airway hyperresponsiveness. Patients with asthma show an exaggerated bronchoconstrictor response, while patients with normal airways tolerate much higher concentrations. A negative methacholine challenge effectively excludes active asthma. The test is useful in patients with respiratory symptoms but normal spirometry at rest.

Cevimeline is a tertiary amine with selective activity at muscarinic subtype 1 and muscarinic subtype 3 receptors, developed specifically for xerostomia in Sjogren syndrome. It has a longer duration of action than pilocarpine and a somewhat lower rate of diaphoresis, making it an alternative for patients who cannot tolerate pilocarpine's sweating side effect. Like pilocarpine, it is contraindicated in uncontrolled asthma and narrow-angle glaucoma.

The edrophonium test exploits the drug's ultrashort duration of action to briefly enhance neuromuscular junction transmission and observe whether a patient's weakness improves. A small dose is given intravenously, and the examiner watches for objectively measurable improvement in a specific sign of weakness: lifting of ptosis (drooping eyelid), improved extraocular muscle movement, increased grip strength, or improved swallowing. A positive result — clear transient improvement that resolves as the drug is eliminated — supports the diagnosis of myasthenia gravis. The test must be performed with atropine and resuscitation capability on hand, because edrophonium's muscarinic effects can produce significant bradycardia, particularly in older patients.

In current clinical practice, the edrophonium test has largely been replaced by serology. Antibodies against the acetylcholine receptor are detected in the large majority of patients with generalized myasthenia gravis and are diagnostic when present. Serological testing is safer, does not require intravenous access and cardiac monitoring, and can be performed in any outpatient setting. The edrophonium test retains a role when rapid bedside confirmation is needed and the clinical situation does not permit waiting for laboratory results.

A hospitalized patient with myasthenia gravis who deteriorates with worsening bulbar and respiratory weakness presents one of the most clinically challenging scenarios in pharmacology: distinguishing between insufficient drug and too much drug. Both myasthenic crisis and cholinergic crisis produce worsening weakness that may require mechanical ventilation. The distinction lies in the accompanying features.

Myasthenic crisis reflects disease progression or under-treatment — there is not enough acetylcholine at the neuromuscular junction to sustain adequate muscle activation. The weakness is not accompanied by signs of muscarinic overstimulation. Cholinergic crisis results from excessive acetylcholinesterase inhibitor dosing: so much acetylcholine accumulates at the neuromuscular junction that the nicotinic receptors become persistently depolarized and unable to respond, producing weakness by a depolarizing block mechanism. At the same time, the same excess acetylcholine overstimulates muscarinic receptors throughout the body, producing the signature features that distinguish cholinergic crisis: copious secretions (bronchorrhea and hypersalivation), bradycardia, miosis, diaphoresis, and gastrointestinal cramping.

Donepezil and galantamine are both metabolized by cytochrome P450 enzymes, specifically the 2D6 and 3A4 isoforms. Potent inhibitors of these enzymes — including fluoxetine and paroxetine for cytochrome P450 2D6, and azole antifungals and clarithromycin for cytochrome P450 3A4 — can substantially raise plasma levels of these drugs when co-administered, increasing the risk of cholinergic adverse effects: nausea, vomiting, diarrhea, and bradycardia. Conversely, cytochrome P450 inducers such as rifampin and carbamazepine accelerate the metabolism of donepezil and galantamine, potentially reducing their therapeutic effect.

Rivastigmine does not undergo cytochrome P450 metabolism and is instead broken down by cholinesterase enzymes directly. This makes rivastigmine the preferred choice for Alzheimer patients who are already taking multiple medications that interact with cytochrome P450 enzymes, since it avoids these pharmacokinetic interactions entirely.

Cardiac glycosides (digoxin) slow the sinoatrial node through a mechanism that includes enhanced vagal tone at muscarinic subtype 2 receptors in the heart. Acetylcholinesterase inhibitors also slow the heart by raising acetylcholine levels at the same muscarinic subtype 2 receptors. When digoxin and an acetylcholinesterase inhibitor are combined, the bradycardic effects are additive, and heart rate monitoring is warranted, particularly when digoxin concentrations are at the high end of the therapeutic range.

Beta-adrenergic blocking agents (beta-blockers) independently slow heart rate by reducing sympathetic input to the sinoatrial node. In combination with an acetylcholinesterase inhibitor, they add another bradycardic influence on top of the cholinergically mediated slowing. The combination requires awareness and heart rate monitoring, particularly in elderly patients with Alzheimer disease who already have a reduced cardiac reserve.

Acetylcholinesterase inhibitors for Alzheimer disease work by raising acetylcholine at central muscarinic receptors. Any drug that blocks muscarinic receptors simultaneously directly opposes this mechanism and negates the therapeutic effect. This pharmacodynamic antagonism is common in clinical practice because many widely used drug classes carry muscarinic blocking activity: tricyclic antidepressants, first-generation antihistamines (diphenhydramine), bladder antimuscarinics (oxybutynin, tolterodine), certain antipsychotics, and antiparkinsonian anticholinergics all have significant muscarinic antagonist properties.

When an acetylcholinesterase inhibitor is initiated for Alzheimer disease, the medication list should be reviewed for drugs with anticholinergic activity. Continuing these agents at the same time as an acetylcholinesterase inhibitor is pharmacologically contradictory and exposes the patient to the adverse effects of both drug classes without obtaining the benefits of either.